Robaxin

(Methocarbamol)

ApprovedSmall molecule

GGrupo Espanol de Tumores Neuroendocrinos

Robaxin is one of 106 small molecule programs targeting Ventral Hernia. It is currently in Approved.

Indications

Total Trials

Active Trials

105

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Ventral HerniaActive, not recruiting

Rib FractureActive, not recruiting

Muscle CrampActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Ventral HerniaApproved

Active, not recruiting

Rib FractureApproved

Active, not recruiting

Muscle CrampPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Adriamycin

39 3

Gemzar

Johnson & Johnson

Phase 3

19 4

Gazyva

Roche

Phase 3

18 5

Eloxatin

Teva

Phase 3

17 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

68 7

Rayos

RRoxane Laboratories

Phase 3

57 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

29 9

COLUMVI

Cytosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedActive, not recruiting

Ventral Hernia

NCT05388929

Clinical

Trials by Indication[1]

Pain Control1 trial

Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

Recruiting·MMayo Clinic·Phase 4·NCT05076110·188 enrolled

Trial1 trial

Japanese IP-TN Trial

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02831569·80 enrolled

Rib Fracture1 trial

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

Completed·MMedical College of Wisconsin·Phase 4·NCT02432456·153 enrolled

Spine Surgery1 trial

Intravenous Methocarbamol for Acute Pain After Spine Surgery

Completed·TThe University of Texas Health Science Center, Houston··NCT06659965·1,270 enrolled

Total Knee Replacement1 trial

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

Completed·AArthritis Innovation Corporation·Phase 3·NCT05603832·151 enrolled

4 more indications

Muscle Cramp1 trial

Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients

Unknown status·TTanta University·Phase 3·NCT02642874·200 enrolled

CAR1 trial

Orphenadrine and Methocarbamol for LBP

Completed·MMontefiore Medical Center·Phase 4·NCT02665286·240 enrolled

Ventral Hernia1 trial

Addition of Methocarbamol to Postoperative Multimodal Analgesic Regimen: A Prospective, Randomized Pilot Study

Active, not recruiting·PPrisma Health-Upstate·Approved·NCT05388929·164 enrolled

Diffuse Large B-Cell Lymphoma1 trial

TRANSCEND FL: Liso-cel in Follicular Lymphoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05100017·118 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ROBAXIN

NDA NDA011790

Jan 1, 1982

ROBAXIN

NDA NDA011011

Jul 30, 2025

ATMEKSI

NDA NDA219843

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Methocarbamol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methocarbamol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methocarbamol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219843). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Robaxin. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Grupo Espanol de Tumores Neuroendocrinos company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGrupo Espanol de Tumores Neuroendocrinos

Patent Landscape[5]

Patent Cliff

Oct 9, 2044

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12390439Oct 9, 2044

Robaxin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pain Control1 trial

Trial1 trial

Rib Fracture1 trial

Spine Surgery1 trial

Total Knee Replacement1 trial

Muscle Cramp1 trial

CAR1 trial

Ventral Hernia1 trial

Diffuse Large B-Cell Lymphoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News